{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T15:29:53Z","timestamp":1771687793361,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thegreenjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.radonc.2017.06.007","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T08:49:47Z","timestamp":1498639787000},"page":"74-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Phase I dose escalation study of concurrent palliative radiation therapy with sorafenib in three anatomical cohorts (Thorax, Abdomen, Pelvis): The TAP study"],"prefix":"10.1016","volume":"124","author":[{"given":"Louise","family":"Murray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Longo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Milosevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Oza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Brade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2017.06.007_b0005","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1097\/MD.0000000000000118","article-title":"Clinical outcome of palliative radiotherapy for locally advanced symptomatic gastric cancer in the modern era","volume":"93","author":"Tey","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.radonc.2017.06.007_b0010","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ijrobp.2011.07.020","article-title":"Radiotherapy for liver metastases: a review of evidence","volume":"82","author":"Hoyer","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.06.007_b0015","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1200\/JCO.2007.15.3312","article-title":"Palliative thoracic radiotherapy for lung cancer: a systematic review","volume":"26","author":"Fairchild","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2017.06.007_b0020","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ygyno.2005.11.047","article-title":"Effective palliative radiotherapy for symptomatic recurrent or residual ovarian cancer","volume":"102","author":"Quon","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.radonc.2017.06.007_b0025","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.radonc.2015.05.021","article-title":"Palliative pelvic radiotherapy for symptomatic incurable prostate cancer \u2013 A prospective multicenter study","volume":"115","author":"Cameron","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2017.06.007_b0030","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","article-title":"Sorafenib (BAY 43\u20139006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","volume":"407","author":"Adnane","year":"2006","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.radonc.2017.06.007_b0035","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.06.007_b0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2017.06.007_b0045","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2017.06.007_b0050","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2017.06.007_b0055","first-page":"5565","article-title":"Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions","volume":"60","author":"Lee","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.06.007_b0060","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1054\/bjoc.2001.2166","article-title":"Effect of VEGF receptor inhibitor PTK787\/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth","volume":"85","author":"Hess","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2017.06.007_b0065","doi-asserted-by":"crossref","first-page":"8587","DOI":"10.1158\/1078-0432.CCR-04-1147","article-title":"ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity","volume":"10","author":"Williams","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.06.007_b0070","first-page":"4009","article-title":"SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models","volume":"63","author":"Schueneman","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.06.007_b0075","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1158\/0008-5472.CAN-04-1668","article-title":"Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy","volume":"65","author":"Huber","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.06.007_b0080","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ijrobp.2004.07.689","article-title":"Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells","volume":"60","author":"Bischof","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.06.007_b0085","first-page":"3755","article-title":"SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro","volume":"63","author":"Abdollahi","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.06.007_b0090","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/28412","article-title":"Combined effects of angiostatin and ionizing radiation in antitumour therapy","volume":"394","author":"Mauceri","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.radonc.2017.06.007_b0095","doi-asserted-by":"crossref","first-page":"8136","DOI":"10.1200\/JCO.2005.02.5635","article-title":"Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients","volume":"23","author":"Willett","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2017.06.007_b0100","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.ijrobp.2005.12.004","article-title":"Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases","volume":"64","author":"Lordick","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.06.007_b0105","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2005.03.6780","article-title":"Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer","volume":"24","author":"Crane","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2017.06.007_b0110","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.ijrobp.2014.01.017","article-title":"Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma","volume":"88","author":"Chen","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.06.007_b0115","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ijrobp.2015.11.048","article-title":"Phase 1 trial of Sorafenib and stereotactic body radiation therapy for hepatocellular carcinoma","volume":"94","author":"Brade","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.06.007_b0120","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3349\/ymj.2013.54.5.1178","article-title":"Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma","volume":"54","author":"Cha","year":"2013","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.radonc.2017.06.007_b0125","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1038\/bjc.2014.209","article-title":"Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma","volume":"110","author":"Hottinger","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2017.06.007_b0130","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijrobp.2012.04.017","article-title":"A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas","volume":"85","author":"Den","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.06.007_b0135","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1245\/s10434-014-3543-7","article-title":"Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity","volume":"21","author":"Canter","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.radonc.2017.06.007_b0140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijrobp.2015.09.009","article-title":"Sorafenib increases tumor hypoxia in cervical cancer patients treated with radiation therapy: results of a phase 1 clinical study","volume":"94","author":"Milosevic","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.06.007_b0145","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijrobp.2014.02.024","article-title":"Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer","volume":"89","author":"Chiorean","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.06.007_b0150","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.radonc.2016.01.018","article-title":"Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma","volume":"118","author":"Kim","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2017.06.007_b0155","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.ijrobp.2012.07.035","article-title":"Phase I Study of Sorafenib and Whole-liver Radiation Therapy (WLRT) or Stereotactic Body Radiation Therapy (SBRT) for liver metastases","volume":"84","author":"Brade","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.06.007_b0160","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2007.15.8451","article-title":"Bowel perforation after radiotherapy in a patient receiving sorafenib","volume":"26","author":"Peters","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2017.06.007_b0165","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijrobp.2013.05.012","article-title":"Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT)","volume":"87","author":"Barney","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.06.007_b0170","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.canrad.2009.01.002","article-title":"[Toxicity of radiation therapy and antiangiogenics combination: a case report]","volume":"13","author":"Diaz","year":"2009","journal-title":"Cancer Radiother"},{"issue":"14","key":"10.1016\/j.radonc.2017.06.007_b0175","first-page":"3374","article-title":"Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation","volume":"59","author":"Gorski","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.06.007_b0180","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2017.06.007_b0185","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.radonc.2017.06.007_b0190","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814017304073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814017304073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T05:29:59Z","timestamp":1535693399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814017304073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0167814017304073"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2017.06.007","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I dose escalation study of concurrent palliative radiation therapy with sorafenib in three anatomical cohorts (Thorax, Abdomen, Pelvis): The TAP study","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2017.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}